NASDAQ$IRWD
Ironwood Pharmaceuticals Inc. · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Ironwood Pharmaceuticals reported positive topline results from global Phase III STARS trial and Phase II exploratory STARGAZE trial, while LINZESS® prescription demand grew 10% year-over-year and financial guidance was revised.
Ironwood Pharmaceuticals reported its first quarter 2024 results, highlighting significant advancements across its portfolio, including positive Phase III clinical data for apraglutide and strong LINZESS demand momentum. The company is working swiftly to file an NDA for apraglutide for adult SBS patients dependent on parenteral support and revised FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate.
- Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF).
- Reported positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease (SR GI aGVHD).
- LINZESS® (Iinaclotide) EUTRx prescription demand growth of 10% year-over-year.
- Revised FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate.
Headline financials
Revenue & EPS history
Ironwood Pharmaceuticals · Revenue · Quarterly
$74.9M
Revenue by segment
Ironwood Pharmaceuticals · $71M total across 1 segment · Q1 2020
- LINZESS Collaboration$71M—100.0%
Forward guidance
Ironwood Pharmaceuticals revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate. The company anticipates low-single digits percentage growth for U.S. LINZESS Net Sales and expects adjusted EBITDA to be greater than $120 million, excluding potential CNP-104 option exercise.
Tailwinds
- U.S. LINZESS Net Sales are expected to grow at a low-single digits percentage.
- Adjusted EBITDA is projected to be greater than $150 million, excluding potential CNP-104 option exercise.
- Adjusted EBITDA is expected to be greater than $120 million, excluding potential CNP-104 option exercise.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-1.0%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-1.2%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+32.8%
Q3 2025
Best reaction
-29.5%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.9% | -15.5% | -31.5% | |
| Q4 2025 | -11.4% | -5.8% | -19.3% | |
| Q3 2025 | +32.8% | +63.5% | +92.2% | |
| Q1 2025 | -4.4% | +0.0% | +5.1% | |
| Q4 2024 | -5.3% | -12.9% | -17.5% | |
| Q3 2024 | -1.6% | -12.9% | -31.9% | |
| Q2 2024 | -29.5% | -25.3% | -25.0% | |
| Q1 2024 | -13.8% | -18.3% | -21.8% | |
| Q4 2023 | -5.6% | -4.0% | -41.6% | |
| Q3 2023 | +5.5% | +5.6% | +13.5% | |
| Q2 2023 | -15.3% | -11.3% | -24.2% | |
| Q1 2023 | +1.5% | -2.4% | +4.9% | |
| Q4 2022 | +5.8% | +3.9% | -7.4% | |
| Q3 2022 | +3.7% | +6.8% | +11.9% | |
| Q2 2022 | +5.9% | +5.6% | -2.9% | |
| Q1 2022 | -3.0% | -8.4% | -9.0% | |
| Q4 2021 | -2.5% | -1.2% | +13.5% | |
| Q3 2021 | +0.4% | -1.2% | -14.6% | |
| Q2 2021 | +3.2% | +4.3% | -1.5% | |
| Q1 2021 | +1.3% | +1.5% | +9.3% | |
| Q4 2020 | -7.0% | -6.6% | +12.3% | |
| Q3 2020 | +4.0% | +12.4% | +16.8% | |
| Q2 2020 | +5.8% | +3.0% | +1.5% | |
| Q1 2020 | -3.2% | +2.5% | -5.3% | |
| Q4 2019 | -3.2% | -2.9% | -18.3% | |
| Q3 2019 | +10.0% | +15.9% | +27.5% | |
| Q2 2019 | +2.6% | -0.8% | -10.0% | |
| Q1 2019 | -9.9% | -12.3% | -7.2% | |
| Q4 2018 | +5.4% | +15.1% | +3.1% | |
| Q3 2018 | -15.6% | -15.9% | -10.3% | |
| Q2 2018 | -1.1% | -1.9% | -1.1% | |
| Q1 2018 | +4.4% | +2.6% | +2.5% | |
| Q4 2017 | +6.0% | +2.4% | +6.0% | |
| Q3 2017 | +6.8% | +1.8% | +16.6% | |
| Q2 2017 | -12.8% | -15.5% | -9.0% | |
| Q1 2017 | +5.2% | +12.9% | +10.5% | |
| Q4 2016 | -1.6% | -4.2% | +0.1% | |
| Q3 2016 | +7.2% | +15.2% | +22.5% | |
| Q2 2016 | -6.0% | -7.7% | -6.9% | |
| Q1 2016 | +9.3% | — | — | |
| Q4 2015 | +3.4% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | -0.1% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | -4.0% | — | — | |
| Q2 2013 | +4.2% | — | — | |
| Q1 2013 | -8.9% | — | — | |
| Q4 2012 | -7.7% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.8% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q1 2012 | -3.5% | — | — | |
| Q4 2011 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q3 2011 | -13.6% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q4 2010 | +0.1% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q1 2010 | -3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro